Jason McCarthy Analyst PerformanceSenior Managing Director, Head of Biotechnology Research at Maxim GroupJason McCarthy is a stock analyst at Maxim Group focused in the medical sector, covering 106 publicly traded companies. Over the past year, Jason McCarthy has issued 39 stock ratings, including buy and hold recommendations. While full access to Jason McCarthy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason McCarthy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings685 Last 10 YearsBuy Recommendations88.28% 595 Buy RatingsCompanies Covered106 Unique Companies Ratings Distribution674RatingsDistribution of strong buy, buy, hold, and sell ratings by Jason McCarthy.RatingPercentageCount Strong Buy0.0%0 ratings Buy88.3%595 ratings Hold11.7%79 ratings Sell0.0%0 ratingsOut of 674 total stock ratings issued by Jason McCarthy at Maxim Group, the majority (88.3%) have been Buy recommendations, followed by 11.7% Hold.Best & Worst CallsBest Call0000000.0%SLSNov 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CRXTQSep 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ76.4% of companies on NASDAQ81 companiesNYSEAMERICAN10.4% of companies on NYSEAMERICAN11 companiesOTCMKTS7.5% of companies on OTCMKTS8 companiesNYSE4.7% of companies on NYSE5 companiesTSE0.9% of companies on TSE1 companyJason McCarthy, an analyst at Maxim Group, currently covers 106 companies listed on NASDAQ, NYSEAMERICAN, OTCMKTS, NYSE and TSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical103 companies97.2%Manufacturing2 companies1.9%Industrials1 company0.9%Jason McCarthy of Maxim Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Industrials companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE49 companies46.2%PHARMACEUTICAL PREPARATIONS18 companies17.0%MED - DRUGS16 companies15.1%MED PRODUCTS6 companies5.7%BIOTECHNOLOGY4 companies3.8%Miscellaneous2 companies1.9%SURGICAL & MEDICAL INSTRUMENTS2 companies1.9%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC2 companies1.9%MEDICAL SERVICES1 company0.9%SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES1 company0.9%MED INSTRUMENTS1 company0.9%DIAGNOSTIC SUBSTANCES1 company0.9%PROTECTION - SFTY1 company0.9%MED - GENERIC DRG1 company0.9%MEDICAL LABORATORIES1 company0.9% About Jason McCarthyJason McCarthy, Ph.D. is a Senior Managing Director and Head of Biotechnology Research at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in Biomedical Sciences at the Albert Einstein College of Medicine. Dr. McCarthy also holds a Master’s degree in both Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University. Jason McCarthy's Ratings History at Maxim Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIMNNImunon4/17/2026Set Price Target$3.09$10.00Buy$0.0000.00% ROIIMNNImunon4/17/2026Initiated Coverage$3.13Buy$0.0000.00% ROIAKTXAkari Therapeutics4/8/2026Downgrade$3.80Hold$0.0000.00% ROIRVPHReviva Pharmaceuticals4/8/2026Downgrade$0.82Hold$0.0000.00% ROITOVXTheriva Biologics3/31/2026Upgrade$0.20$1.00Buy$0.0000.00% ROIMNOVMediciNova3/23/2026Reiterated Rating$1.56$6.00Buy$0.0000.00% ROISLSSELLAS Life Sciences Group3/12/2026Boost Price Target$5.37$10.00Buy$0.0000.00% ROICLRBCellectar Biosciences3/10/2026Upgrade$2.75Buy$0.0000.00% ROIPLYXPolaryx Therapeutics2/27/2026Initiated Coverage$3.19$10.00Buy$0.0000.00% ROICODXCo-Diagnostics1/23/2026Downgrade$2.92Hold$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. VTGNVistaGen Therapeutics12/17/2025Reiterated Rating$0.86Hold$0.0000.00% ROIRZLTRezolute12/12/2025Set Price Target$1.60$4.00$0.0000.00% ROICAPRCapricor Therapeutics12/4/2025Boost Price Target$23.17$50.00Buy$0.0000.00% ROICODXCo-Diagnostics11/26/2025Upgrade$0.36Hold$0.0000.00% ROICODXCo-Diagnostics11/26/2025Initiated Coverage$9.75$45.00Buy$0.0000.00% ROIARTLArtelo Biosciences11/19/2025Reiterated Rating$1.84Hold$0.0000.00% ROICEROCERo Therapeutics11/3/2025Downgrade$0.13Hold$0.0000.00% ROIABPAbpro10/21/2025Downgrade$0.20Hold$0.0000.00% ROIGANXGain Therapeutics10/7/2025Boost Price Target$2.02$7.00Buy$0.0000.00% ROIHINDVyome10/2/2025Reiterated Rating$5.50$15.00Buy$0.0000.00% ROIHINDVyome10/2/2025Reiterated Rating$5.36$15.00Buy$0.0000.00% ROIADILAdial Pharmaceuticals9/30/2025Upgrade$8.31$37.50Buy$0.0000.00% ROIAZTRAzitra9/24/2025Lower Price Target$0.73$4.00Buy$0.0000.00% ROIRZLTRezolute9/18/2025Boost Price Target$8.33$20.00Buy$0.0000.00% ROICNSPCNS Pharmaceuticals9/12/2025Upgrade$7.74$20.00Buy$0.0000.00% ROINEUPNeuphoria Therapeutics9/11/2025Boost Price Target$14.06$35.00Buy$0.0000.00% ROICHRSCoherus Oncology9/4/2025Upgrade$1.26$4.00Buy$0.0000.00% ROIPSTVPlus Therapeutics8/18/2025Lower Price Target$13.78$75.00Buy$0.0000.00% ROIRVPHReviva Pharmaceuticals8/15/2025Lower Price Target$10.80$40.00Buy$0.0000.00% ROIBCLIBrainstorm Cell Therapeutics7/23/2025Downgrade$0.71Hold$0.0000.00% ROIAKTXAkari Therapeutics7/18/2025Initiated Coverage$45.20$200.00Buy$0.0000.00% ROISLSSELLAS Life Sciences Group7/16/2025Boost Price Target$1.87$7.00Buy$0.0000.00% ROIINMBINmune Bio7/2/2025Lower Price Target$2.34$8.00Buy$0.0000.00% ROICTXRCitius Pharmaceuticals5/23/2025Downgrade$0.72Hold$0.0000.00% ROIMTVAMetaVia5/19/2025Lower Price Target$7.48$33.00Buy$0.0000.00% ROICEROCERo Therapeutics5/19/2025Initiated Coverage$11.80$60.00Buy$0.0000.00% ROICLRBCellectar Biosciences5/14/2025Reiterated Rating$0.24Hold$0.0000.00% ROIPMNPromis Neurosciences5/12/2025Initiated Coverage$12.41$75.00Buy$0.0000.00% ROITOVXTheriva Biologics5/8/2025Reiterated Rating$0.81Hold$0.0000.00% ROIKAPAKairos Pharma3/27/2025Initiated Coverage$0.93$4.00Buy$0.0000.00% ROICNSPCNS Pharmaceuticals3/25/2025Reiterated Rating$1.45Hold$0.0000.00% ROIANIXAnixa Biosciences3/21/2025Initiated Coverage$3.15$10.00Buy$0.0000.00% ROIONCYOncolytics Biotech3/10/2025Lower Price Target$0.65$3.00Buy$0.0000.00% ROIABPAbpro2/24/2025Initiated Coverage$23.75$120.00Buy$0.0000.00% ROIINMBINmune Bio2/13/2025Boost Price Target$9.30$30.00Buy$0.0000.00% ROIKZIANovogen2/6/2025Initiated Coverage$7.00$15.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
